These data indicate that TLR3 expression on immune cells in the lung can be detrimental, and that TLR3-positive tumor macrophages might reveal an immunosuppressive context that contribute to sustain the progression of early stage NSCLC. The gene discussed is TLR3; the disease is neoplasm.